Health Care Archives - Page 26 of 478

2 minute read

Second Death – Pfizer Reports Young Boy’s Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial

May 8, 1:09 PM

A young patient passed away from cardiac arrest after receiving Pfizer's experimental gene therapy for Duchenne muscular dystrophy. Pfizer investigates while trials continue, including Phase 3 study. Second death associated with the therapy.

PFE

2 minute read

AstraZeneca Pulls Plug On Vaxzevria COVID-19 Vaccine Amid Surplus of Updated Vaccines

By Benzinga Neuro

May 8, 6:23 AM

It is worth noting that AstraZeneca has previously conceded in court documents that Vaxzevria can induce side effects such as blood clots and low blood platelet counts.

AZN

2 minute read

Nano-Cap Eledon Pharmaceuticals’ Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence

By Vandana Singh

May 7, 3:40 PM

Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant advancements, reflecting in raised price targets.

ELDN

1 minute read

Johnson & Johnson’s TARIS Platform – Goldman Sachs Outlines Potential For The Bladder Cancer Therapy

By Vandana Singh

May 7, 2:31 PM

Johnson & Johnson unveils promising TARIS platform data for bladder cancer treatment, highlighting ease of administration and significant revenue potential.

JNJ

2 minute read

Dental Supplies Distributor Henry Schein’s Tech Segment Provides Some Stability In Challenging Macro Times: Analyst

By Vandana Singh

May 7, 2:27 PM

Henry Schein reports Q1 adjusted EPS at $1.10, down 9% Y/Y, with sales at $3.17 billion, up 3.7%. Guidance projects 2024 sales growth at 8%-10%, reaffirming adjusted EPS guidance of $5.00-$5.16. William Blair attributes the EPS beat to margin expansion driven by technology and value-added services.

HSIC

2 minute read

Band-Aid Maker Kenvue Cuts Workforce By 4%, Q1 Earnings Beat Street Expectations

By Vandana Singh

May 7, 12:52 PM

Kenvue's first-quarter sales of $3.89 billion. Organic growth surged by 1.9% amidst strong demand in Self Care and Essential Health segments. Kenvue's strategic workforce reduction and targeted cost savings.

KVUE

1 minute read

What About Eli Lilly’s Drug For Early Alzheimer’s? FDA Panel To Discuss Next Month

By Vandana Singh

May 7, 12:38 PM

FDA's advisory committee meeting on June 10, 2024, discussing Eli Lilly's donanemab for early Alzheimer's.

LLY

2 minute read

FDA Experts Weigh In On Incannex’s CannQuit-O With Feedback On CBD As Treatment For Opioid Use Disorder

By Jelena Martinovic

May 7, 12:35 PM

Incannex Healthcare Inc., a cannabinoid and psychedelic medicine biotechnology company, announced the successful completion of a pre-investigational new drug meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-O for the treatment of opioid use disorder (OUD).A number of FDA representatives shared insights on the CannQuit-O development program during the pre-IND teleconference in addition to providing recommendations on the proposed clinical development strategy.

IXHL

2 minute read

US Healthcare Landlord Medical Properties Trust’s Largest Tenant Steward Health Goes Bankrupt, Sparks Regulatory Concerns

By Vandana Singh

May 7, 10:37 AM

Amid Chapter 11 bankruptcy, Steward Health Care, Medical Properties Trust's tenant, faces financial turmoil. State regulators scrutinize its 30 hospitals, grappling with incidents like bat evacuations, unpaid nurses, and equipment shortages. Steward's reliance on MPW for a $300 million loan raises eyebrows, as stakeholders navigate complex ties amid regulatory interventions.

MPW

2 minute read

Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars

By Vandana Singh

May 7, 10:20 AM

Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024 revenue guidance: $225-$245 million.

ESPR